Ets-1 deficiency leads to altered B cell differentiation, hyperresponsiveness to TLR9 and autoimmune disease
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
It has been shown that mice with a targeted mutation in the Ets-1 gene exhibit increased B cell terminal differentiation to IgM-secreting plasma cells. Here, we show that mice, formerly described to lack Ets-1 protein, actually express low levels of an internally deleted Ets-1 protein. Mice harboring this Ets-1 hypomorphic allele possess very few marginal zone B cells and have increased expression of activation markers on follicular B cells. Adoptive transfer experiments indicate that this activated phenotype can be reversed upon transfer of Ets-1-deficient B cells to a wild-type host, suggesting a role for B cell-extrinsic factors in regulating the activated state. Supporting this observation, the reverse transfer experiment of wild-type B cells into an Ets-1-deficient host resulted in increased expression of activation markers on the transferred B cells. However, there are also cell-intrinsic changes in Ets-1-deficient B cells as demonstrated by their increased differentiation to plasma cells in vitro in response to stimulation with cytosine-phosphate-guanine DNA sequence-containing oligodeoxynucleotide [CpG DNA, a Toll-like receptor (TLR) 9 ligand]. Consistent with the activated phenotype and increased terminal differentiation of Ets-1-deficient B cells, Ets-1 mutant mice develop autoimmune disease. Hence, our studies establish Ets-1 as an important regulator of peripheral B cell differentiation and B cell responses to TLR9 activation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Direct Repression of prdm1 by Bcl-6 Inhibits Plasmacytic Differentiation
Tunyaplin, C., Shaffer, A. L., Angelin-Duclos, C. D., Yu, X., Staudt, L. M., & Calame, K. L. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.2.1158 · Cited by 376
Yang, B.-S., Hauser, C. A., Henkel, G., Colman, M. S., Beveren, C. V., Stacey, K. J., Hume, D. A., Maki, R. A., & Ostrowski, M. C. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.2.538 · Cited by 333 · cited 2×
“The Pointed domain of Ets-1 interacts with Erk kinases, which subsequently phosphorylate Ets-1 on a threonine residue (T38) located upstream of the Pointed domain (9, 10 , 23).”
BackgroundDefective activation and survival of T cells lacking the Ets-1 transcription factor
Muthusamy, N., Barton, K., & Leiden, J. M. (1995) · Nature · doi:10.1038/377639a0 · Cited by 330
Self-citationAiolos Regulates B Cell Activation and Maturation to Effector State
Wang, J.-H., Avitahl, N., Cariappa, A., Friedrich, C., Ikeda, T., Renold, A., Andrikopoulos, K., Liang, L., Pillai, S., Morgan, B. A., et al. (1998) · Immunity · doi:10.1016/s1074-7613(00)80637-8 · Cited by 321
Regulation of lymphoid-specific immunoglobulin mu heavy chain gene enhancer by ETS-domain proteins
Nelsen, B., Tian, G., Erman, B., Gregoire, J., Maki, R., Graves, B., & Sen, R. (1993) · Science · doi:10.1126/science.8316859 · Cited by 222 · cited 1×
“Indeed, Ets-1 has been reported to directly bind to the Ig heavy chain intronic enhancer and to contribute to the activity of this enhancer element ( 30 ).”
BackgroundRas/Mitogen-Activated Protein Kinase Signaling Activates Ets-1 and Ets-2 by CBP/p300 Recruitment
Foulds, C. E., Nelson, M. L., Blaszczak, A. G., & Graves, B. J. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.24.10954-10964.2004 · Cited by 190
Wasylyk, C., Bradford, A. P., Gutierrez-Hartmann, A., & Wasylyk, B. (1997) · Oncogene · doi:10.1038/sj.onc.1200914 · Cited by 101
Eyquem, S., Chemin, K., Fasseu, M., Chopin, M., Sigaux, F., Cumano, A., & Bories, J. (2004) · European Journal of Immunology · doi:10.1002/eji.200425352 · Cited by 52
Cited by
Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease
Onishi, R. M., & Gaffen, S. L. (2010) · Immunology · doi:10.1111/j.1365-2567.2009.03240.x · Cited by 894
Yang, W., Shen, N., Ye, D.-Q., Liu, Q., Zhang, Y., Qian, X.-X., Hirankarn, N., Ying, D., Pan, H.-F., Mok, C. C., et al. (2010) · PLoS Genetics · doi:10.1371/journal.pgen.1000841 · Cited by 404
Genetic susceptibility to systemic lupus erythematosus in the genomic era
Deng, Y., & Tsao, B. P. (2010) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2010.176 · Cited by 379
“An important role for ETS1 in the pathogenesis of SLE was demonstrated using Ets1 -deficient mice that developed a lupus-like disease characterized by high titers of autoantibodies and local activation of complement”
BackgroundGenetics and pathogenesis of systemic lupus erythematosus and lupus nephritis
Mohan, C., & Putterman, C. (2015) · Nature Reviews Nephrology · doi:10.1038/nrneph.2015.33 · Cited by 377
Extrafollicular responses in humans and SLE
Jenks, S. A., Cashman, K. S., Woodruff, M. C., Lee, F. E., & Sanz, I. (2019) · Immunological Reviews · doi:10.1111/imr.12741 · Cited by 317
Metadata
- Authors
- Wang, D., John, S. A., Clements, J. L., Percy, D. H., Barton, K. P., & Garrett-Sinha, L. A.
- Venue
- International Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-07-28
- Volume
- 17
- Issue
- 9
- Pages
- 1179-1191
- ISSN
- 0953-8178 (ISSN-L)
- 1460-2377
- OpenAlex
- W2136807721
- Cited by
- 119
- References
- 8
- FWCI
- 1.18
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ets-1 deficiency leads to altered B cell differentiation, hyperresponsiveness to TLR9 and autoimmune disease. https://app.cochat.ai/papers/10.1093/intimm/dxh295
- The paper
- Wang, D., John, S. A., Clements, J. L., Percy, D. H., Barton, K. P., & Garrett-Sinha, L. A. (2005). Ets-1 deficiency leads to altered B cell differentiation, hyperresponsiveness to TLR9 and autoimmune disease. International Immunology. https://doi.org/10.1093/intimm/dxh295
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.